ReCAP

Key Updates in Early Breast Cancer From SABCS 2024 Key updates from SABCS 2024 in early breast cancer include the COMET study on DCIS recurrence, INSEMA trial on SLNB omission, and OlympiA updates on adjuvant olaparib, shared by Dr Harold Burstein.
January 09, 2025
Updates in ER-Positive Breast Cancer From SABCS 2024 Updates in ER+ breast cancer from SABCS 2024 include the EMBER-3 trial of novel oral SERD imlunestrant, PATINA trial results, and updated analysis from TAILORx, as reported by Dr Harold Burstein.
January 02, 2025
Key Studies in Acute Lymphoblastic Leukemia From ASH 2024 Highlights in acute lymphoblastic leukemia (ALL) from ASH 2024 include significant results for blinatumomab in pediatric ALL, potential use of asciminib, and frontline use of CAR-T cell therapy.
January 02, 2025
Key Studies in Chronic Lymphocytic Leukemia From ASH 2024 Practice-changing studies in both frontline CLL and relapsed/refractory disease, presented at ASH 2024, are discussed by Dr Jennifer Woyach.
December 30, 2024
Paroxysmal Nocturnal Hemoglobinuria Takeaways From ASH 2024 Symptom improvement with novel therapies and better patient-reported outcomes, as well as breakthrough hemolysis control, are among the paroxysmal nocturnal hemoglobinuria highlights from ASH 2024.
December 30, 2024
Novel Insights in Thrombotic Disorders From ASH 2024 Rilzabrutinib and eltrombopag in immune thrombocytopenia, and the place of oral direct anticoagulation in venous thromboembolism, are among the novel insights in thrombotic disorders from ASH 2024.
December 30, 2024
DLBCL Highlights From ASH 2024 Dr John Leonard shares key updates on DLBCL at ASH 2024, including long-term POLARIX trial data, ctDNA insights, and real-world results for polatuzumab, liso-cel, and bispecifics after CAR-T failure.
December 30, 2024
Chronic Myeloid Leukemia Highlights From ASH 2024 Highlights in chronic myeloid leukemia from ASH 2024 include data on efficacy of asciminib over TKIs, benefit from the third-generation TKI olverembatinib, and importance of molecular monitoring.
December 30, 2024
New Directions in Anemia and Related Disorders From ASH 2024 Strategies to reduce disease burden in alpha- or beta-thalassemia, sickle cell disease, and polycythemia vera, and insights into anemia in IBD, are among anemia highlights from ASH 2024.
December 23, 2024
Psoriatic Arthritis Highlights From ACR Convergence 2024 Highlights in psoriatic arthritis from ACR 2024 include results of methotrexate added to DMARD therapy, responses to bimekizumab, and improvements gained by upadacitinib after prior TNF inhibitor use.
December 11, 2024
Highlights in Food Allergy Studies From ACAAI 2024 Key food allergy studies from ACAAI 2024 include data on the pharmacokinetics of different epinephrine delivery methods, early allergen exposure, and food allergy anxiety in children and caregivers.
November 18, 2024
Glomerular Disease Highlights From ASN Kidney Week 2024 Glomerular disease highlights from ASN 2024 include data on atacicept benefits in IgA nephropathy, protein reduction from pegcetacoplan, and a possible new therapy for membranous nephropathy.
November 13, 2024
ASRS 2024 Dry AMD Highlights From ASRS 2024 Key data on dry age-related macular degeneration and geographic atrophy from ASRS 2024 include real-world experience of recently approved therapies and emerging agents with new mechanisms of action.
ReCAP, November 12, 2024
Myasthenia Gravis Highlights From AANEM 2024 Highlights in myasthenia gravis from AANEM 2024 include efficacy data on efgartigimod, ravulizumab, zilucoplan, and first-in-class inebilizumab, as well as safety outcomes in pregnancy for eculizumab.
November 08, 2024
Age-Related Macular Degeneration Highlights From AAO 2024 Practice-changing studies in dry age-related macular degeneration (AMD) and promising new directions in wet AMD, presented at AAO 2024, are discussed by Dr Sunir Garg of Wills Eye Hospital.
November 06, 2024
Multiple Sclerosis Highlights From ECTRIMS 2024 Highlights in relapsing-remitting multiple sclerosis from ECTRIMS 2024 include treatment for pediatric-onset MS, safety of frexalimab, pregnancy-related considerations, and efficacy of tolebrutinib.
October 10, 2024
Wet AMD: Advances From ASRS 2024 Wet AMD highlights from ASRS 2024 are discussed by Dr Arshad Khanani, including an update on gene therapies and 4-year results of faricimab in DME that may presage long-term use in wet AMD.
August 09, 2024
Myelofibrosis Highlights From EHA 2024 Highlights in myelofibrosis from EHA 2024 include results of pelabresib-ruxolitinib combination therapy, final analysis of jaktinib compared to hydroxyurea, and safety and efficacy of elritercept.
July 05, 2024
Key Data in Rheumatoid Arthritis From EULAR 2024 Key data in rheumatoid arthritis (RA) from EULAR 2024 include abatacept vs adalilmumab in early RA, the effect of DMARDs on development of interstitial lung disease, and results of the TREAT EARLIER trial.
July 03, 2024
Advanced Non-Small Cell Lung Cancer Updates From ASCO 2024 Practice-changing studies in advanced non-small cell lung cancer presented at ASCO 2024 are reviewed by Dr Ticiana Leal, including the phase 3 LAURA and PALOMA-3 studies and a 5-year update of CROWN.
June 26, 2024

All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.